India’s largest drugmaker Sun Pharmaceutical Industries is exploring the acquisition of US-based women’s healthcare specialist Organon, in a transaction estimated at around $10 billion including debt, according to multiple media reports. The discussions, still at an exploratory stage, underline Sun Pharma’s intent to accelerate its scale and relevance in the US pharmaceutical market, nearly a decade after its transformative acquisition of Ranbaxy.

Sun Pharma has reportedly engaged a European investment bank to advise on the structuring of a comprehensive financial proposal that could eventually be presented to Organon’s board. While there is no certainty of a transaction at this stage, the renewed talks signal a revival of negotiations that had earlier stalled due to valuation disagreements. The reset has been driven in part by a sharp correction in Organon’s share price and its ongoing efforts to pare debt through asset sales.

Organon was spun off from Merck Sharp & Dohme in 2021, inheriting a heavy debt load of roughly $9.5 billion at inception. Since then, it has pursued selective inorganic growth, including the $1.2 billion acquisition of Dermavant from Roivant in 2024, which added to leverage pressures. As of the second quarter of 2025, Organon’s net debt stood at about $8.9 billion, prompting the company to divest non-core assets and refocus on its core women’s health and biosimilars franchise.

For Sun Pharma, the timing is notable. The company has steadily strengthened its balance sheet, with minimal standalone debt and sizeable cash reserves, even as it invests aggressively in innovation-led assets. Its recent acquisitions of Checkpoint Therapeutics and Concert Pharma highlight a clear strategic shift toward differentiated, branded, and specialty therapies rather than volume-led generics.

The potential acquisition of Organon would represent a decisive step-change in Sun Pharma’s US strategy. Organon brings with it a large and established portfolio in women’s contraception and fertility, led by products such as Nexplanon, Nuvaring, and Follistim, alongside a growing biosimilars business developed in partnership with Samsung Bioepis. These are segments where Sun Pharma currently has limited scale, despite a growing base of innovative dermatology and oncology products in the US.

At an enterprise value of roughly $10 billion, the deal would dwarf Sun Pharma’s previous overseas acquisitions and could become the largest cross-border transaction ever undertaken by an Indian pharmaceutical company. Importantly, Organon’s market capitalisation is significantly lower than its debt, reflecting investor concerns around governance, sales practices, and leadership stability following the exit of its former CEO.

Strategically, the transaction could reposition Sun Pharma from being primarily a strong India-centric and specialty-focused global player to a more diversified US-facing branded pharmaceutical company. Women’s health and biosimilars are seen as relatively resilient and less crowded compared to traditional generics, offering longer product lifecycles and steadier pricing dynamics.

For the Indian pharmaceutical sector, such a deal would mark a shift in ambition. Historically, large overseas acquisitions by Indian firms have focused on scale in generics. This move, by contrast, would be about portfolio depth, therapeutic adjacency, and long-term innovation positioning.

Both companies have declined to comment on market speculation. However, industry experts cited in media reports have pointed to Sun Pharma founder Dilip Shanghvi’s track record in complex turnarounds, including Taro and Ranbaxy, as a key factor underpinning confidence in Sun Pharma’s ability to absorb and stabilise a leveraged global asset like Organon.

Organon, for its part, has communicated to investors that from 2026 onwards it aims to expand EBITDA, sharpen its R&D focus, and strengthen growth drivers—signals that it remains open to strategic alternatives amid ongoing balance sheet constraints.

If executed, the combined entity’s pro forma leverage is expected to be manageable, supported by Sun Pharma’s strong cash position. However, the integration challenge would be significant, given Organon’s regulatory exposure, US-centric operations, and ongoing restructuring.

For Indian markets, the announcement phase itself is likely to be met with cautious optimism. While the long-term strategic logic may appeal to investors focused on innovation and global scale, near-term concerns around leverage, execution risk, and regulatory scrutiny in the US could weigh on sentiment.